tumour and blood samples: Tumour and blood samples
Study summary
This study comprises 3 stages:
1. Collection of tumor and blood samples.
2. Creation of organoid models based on tumor samples.
3. Development of functional tests to predict clinical response to treatment.
Eligibility
Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patient aged 18 years or more
* Patient with histologically confirmed, localized endometrial cancer, candidate for surgical treatment.
* Patient with localized endometrial cancer, presenting:
* A high-grade endometrioid histological type and/or
* P53 mutation and/or
* a non-endometrioid histological type regardless of P53 status.
* Patient affiliated to a social security scheme
* Information and signature of informed consent prior to any specific study procedure
Exclusion Criteria:
* Other active cancer less than 6 months old (with the exception of treated basal cell carcinoma of the skin).
* Patient deprived of liberty, under guardianship, or subject to a legal protection measure, or unable to express consent.
Primary outcome measure(s)
Rate of establishment of exploitable tumor organoid lines — through study completion, an average of 3 years Rate of establishment of tumor organoid lines usable for predictive assays of response to PARP inhibitors.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
